Zentrum fur klinische Studien Bad Homburg
- Address
- Louisenstrasse, 63, 61348 Bad Homburg, Germany
Cardiovascular Diseases
At Zentrum fur klinische Studien Bad Homburg, the main focus is on cardiovascular diseases, with studies centered on conditions such as atherosclerotic cardiovascular disease, atrial fibrillation, hypertension, and heart failure prevention. These trials are designed to assess new treatments, reduce major cardiovascular events, and improve long-term risk control for people with established or high-risk heart disease.
- Testing therapies to prevent stroke, heart attack, and other major cardiovascular events
- Studying treatments for atrial fibrillation and related embolic risk
- Evaluating approaches for resistant and uncontrolled hypertension
- Assessing therapies aimed at lowering LDL cholesterol and lipoprotein(a)
The site’s cardiovascular research also includes work on lipid disorders and vascular risk reduction, reflecting a strong interest in improving both prevention and treatment effectiveness in everyday clinical care.
Nutritional and Metabolic Diseases
The site also conducts trials in nutritional and metabolic diseases, especially obesity, overweight, type 2 diabetes, and related cardiometabolic conditions. These studies aim to evaluate new options for weight management, support better metabolic health, and explore whether treatment can lower the risk of future cardiovascular complications.
- Investigating therapies for obesity and chronic weight management
- Studying treatments in people with overweight and metabolic risk
- Exploring care for type 2 diabetes alongside cardiovascular disease
- Assessing whether metabolic treatments can also improve cardiovascular outcomes
Research at Kardiopraxis Bad Homburg connects weight and metabolic health with heart disease prevention, showing a clear emphasis on integrated care for patients with overlapping risk factors.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novartis Pharma AG2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zentrum fur klinische Studien Bad Homburg
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rosuvastatin | 2 | Unknown | 2022-04-08 | 2024-06-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.